126 related articles for article (PubMed ID: 17106369)
1. Considerations in developing model-based economic evaluations of glaucoma treatment.
Althin R; Grima DT; Dhawan R; Bernard LM
J Glaucoma; 2006 Dec; 15(6):541-7. PubMed ID: 17106369
[TBL] [Abstract][Full Text] [Related]
2. Economic considerations of the diagnosis and management for glaucoma in the developed world.
Tuulonen A
Curr Opin Ophthalmol; 2011 Mar; 22(2):102-9. PubMed ID: 21192264
[TBL] [Abstract][Full Text] [Related]
3. The long term effectiveness and cost-effectiveness of initiating treatment for ocular hypertension.
van Gestel A; Schouten JS; Beckers HJ; Severens JL; Hendrikse F; Webers CA
Acta Ophthalmol; 2014 Sep; 92(6):513-23. PubMed ID: 24330516
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of treating ocular hypertension.
Stewart WC; Stewart JA; Nasser QJ; Mychaskiw MA
Ophthalmology; 2008 Jan; 115(1):94-8. PubMed ID: 18166406
[TBL] [Abstract][Full Text] [Related]
5. Costs of treating primary open-angle glaucoma and ocular hypertension: a retrospective, observational two-year chart review of newly diagnosed patients in Sweden and the United States.
Kobelt-Nguyen G; Gerdtham UG; Alm A
J Glaucoma; 1998 Apr; 7(2):95-104. PubMed ID: 9559495
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness.
Tuulonen A; Azuara-Blanco A
Ophthalmology; 2009 Jan; 116(1):166-7; author reply 167. PubMed ID: 19118707
[No Abstract] [Full Text] [Related]
7. Cost-effectiveness.
Brown GC; Brown MM
Ophthalmology; 2008 Aug; 115(8):1433; author reply 1433-4. PubMed ID: 18675701
[No Abstract] [Full Text] [Related]
8. Modeling complex treatment strategies: construction and validation of a discrete event simulation model for glaucoma.
van Gestel A; Severens JL; Webers CA; Beckers HJ; Jansonius NM; Schouten JS
Value Health; 2010; 13(4):358-67. PubMed ID: 20659272
[TBL] [Abstract][Full Text] [Related]
9. Glaucoma in the United States and europe: predicting costs and surgical rates based upon stage of disease.
Lee PP; Kelly SP; Mills RP; Traverso CE; Walt JG; Doyle JJ; Katz LM; Siegartel LR;
J Glaucoma; 2007 Aug; 16(5):471-8. PubMed ID: 17700290
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness.
Lichter PR
Ophthalmology; 2008 Oct; 115(10):1852-3; author reply 1853. PubMed ID: 18929170
[No Abstract] [Full Text] [Related]
11. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB
Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
[TBL] [Abstract][Full Text] [Related]
12. A multicentre, retrospective study of resource utilization and costs associated with glaucoma management in France and Sweden.
Lindblom B; Nordmann JP; Sellem E; Chen E; Gold R; Polland W; Williamson W; Buchholz P; Walt JG; Groleau D; Curry A; Evans SJ
Acta Ophthalmol Scand; 2006 Feb; 84(1):74-83. PubMed ID: 16445443
[TBL] [Abstract][Full Text] [Related]
13. Latanoprost versus timolol as first choice therapy in patients with ocular hypertension. A cost-effectiveness analysis.
Peeters A; Schouten JS; Severens JL; Hendrikse F; Prins MH; Webers CA
Acta Ophthalmol; 2012 Mar; 90(2):146-54. PubMed ID: 20731623
[TBL] [Abstract][Full Text] [Related]
14. Comment on 'What is the direct cost of treatment of acute primary angle closure glaucoma? The Singapore model'.
Papalkar D; Francis IC; Lim R
Clin Exp Ophthalmol; 2005 Aug; 33(4):446; author reply 447. PubMed ID: 16033375
[No Abstract] [Full Text] [Related]
15. Medical Costs of and Changes in Glaucoma Treatment among Patients Newly Starting Glaucoma Care.
Fukuda Y; Kume A; Kashiwagi K
Curr Eye Res; 2021 Nov; 46(11):1695-1702. PubMed ID: 33843390
[No Abstract] [Full Text] [Related]
16. A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma.
Lee PP; Walt JG; Doyle JJ; Kotak SV; Evans SJ; Budenz DL; Chen PP; Coleman AL; Feldman RM; Jampel HD; Katz LJ; Mills RP; Myers JS; Noecker RJ; Piltz-Seymour JR; Ritch RR; Schacknow PN; Serle JB; Trick GL
Arch Ophthalmol; 2006 Jan; 124(1):12-9. PubMed ID: 16401779
[TBL] [Abstract][Full Text] [Related]
17. Treatment of glaucoma in clinical practice: four-year results from a patient registry in France.
Kobelt G; Texier-Richard B; Buchholz P; Bron A; Renard JP; Rouland JF; Nordmann JP
J Glaucoma; 2010 Mar; 19(3):199-206. PubMed ID: 19661825
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications.
Noecker RJ; Walt JG
Am J Ophthalmol; 2006 Jan; 141(1 Suppl):S15-21. PubMed ID: 16389056
[TBL] [Abstract][Full Text] [Related]
19. How prostaglandins have changed the medical approach to glaucoma and its costs: an observational study of 2228 patients treated with glaucoma medications.
De Natale R; Draghi E; Dorigo MT
Acta Ophthalmol Scand; 2004 Aug; 82(4):393-6. PubMed ID: 15291930
[TBL] [Abstract][Full Text] [Related]
20. Glaucoma costs in Denmark in treatment naive patients.
Olsen J; Berdeaux G; Skov J
Acta Ophthalmol; 2013 Feb; 91(1):25-31. PubMed ID: 21834919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
